While increased p16 accelerates cellular senescence, which is considered a safe guard mechanism against carcinogenesis, reports in literature also demonstrate upregulation of p16 in a number of cancers and increased p16 was associated with poor prognosis [25]. This evidence concerns the gene CDKN2A and cancer.